Bizily Scott sold $118K of FDMT
Bizily Scott (Chief Legal Officer) sold 9,810 shares of 4D Molecular Therapeutics, Inc. (FDMT) at $12.00 ($0.12M total) on 2026-06-23 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the specific sale size, price ($12.00), and post-transaction holdings (8,617 shares) by the Chief Legal Officer under a 10b5-1 plan.
Market read
Traders may note the insider selling activity, but the planned nature and modest size relative to typical market-moving thresholds suggest limited impact.
What to watch
Consider whether multiple insiders filed similar transactions around the same window; one Form 4 alone is usually not a standalone catalyst.
Background
The article is an SEC EDGAR Form 4 insider transaction disclosure for 4D Molecular Therapeutics, Inc.
Ticker impact
SEC Form 4 shows CFO Bizily Scott sold 9,810 shares of FDMT at $12.00/share under a pre-arranged 10b5-1 plan.
Low near-term impact; any reaction is likely muted unless paired with other new company-specific catalysts.
The filing is a Form 4 insider transaction with a stated 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.
Market effects
No clear sector read-through from a single planned insider sale.
None indicated.
None indicated.
Counterpoint
Insider sales can still coincide with private information, but the presence of a 10b5-1 plan makes that inference weaker.
Key entities
- issuer4D Molecular Therapeutics, Inc.
Subject of the Form 4 insider sale disclosure (FDMT).
- insiderBizily Scott
Chief Legal Officer who sold 9,810 shares under a pre-arranged 10b5-1 plan.
